A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

  • End date
    Nov 15, 2022
  • participants needed
  • sponsor
    Clexio Biosciences Ltd.
Updated on 18 May 2022


The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy. The objective of the study is to assess CLE-100 for the treatment of MDD in participants currently treated with standard antidepressant therapy.


CLEO study is performed in two parts (part A and Part B). The sponsor is currently recruiting only for the Part B of the study.

Part A will be an inpatient study to assess the safety, tolerability, and pharmacokinetics of CLE-100 (oral esketamine) in MDD participants currently treated with an antidepressant drug. It will include a screening phase (up to 35 days), a 1 week inpatient double-blind treatment phase and an outpatient post treatment safety follow-up phase of 1 week after last study drug administration.

Part B will be a study to assess the safety and efficacy of CLE-100 (oral esketamine) in MDD participants currently treated with an antidepressant drug with inadequate response to standard antidepressant therapy.

The participants will remain on their current antidepressant therapy with no dose change during the study.

Condition Adjunctive Treatment of Major Depressive Disorder
Treatment Placebo, CLE-100
Clinical Study IdentifierNCT04103892
SponsorClexio Biosciences Ltd.
Last Modified on18 May 2022


Yes No Not Sure

Inclusion Criteria

Male or female between 18 to 65 years of age
Primary diagnosis of MDD without psychotic features according to DSM-5 and supported by the Mini International Neuropsychiatric Interview (MINI)
MADRS score of at least 24 at Screening
At least 2 inadequate responses to antidepressant therapy (ADT) in the current Major Depressive Episode (MDE)
Current MDE for at least 12 weeks
BMI between 18 and 40 kg/m2, inclusive
Is able and competent to read and sign the ICF

Exclusion Criteria

Inadequate response to more than 5 treatment courses of antidepressant medication therapy during the current MDE
Current MDE for longer than 5 years
3\. Has a current substance use disorder or history of any substance use disorder per DSM-5 criteria within 12 months prior to Screening, except for tobacco use disorder
Has a history or current diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorders
Has dementia, delirium, amnesia, or any other significant cognitive disorder
Has posttraumatic stress disorder, obsessive compulsive disorder, or any other mental disorder (including personality disorders, eating disorders, etc.)
Has any medical condition for which an increase in blood pressure or intracranial pressure poses a serious risk
Has been randomized in Part A of this study
Is a female of childbearing potential pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note